Tony Giordano
About Tony Giordano
Tony Giordano Chief Scientific Officer
Tony Giordano serves as the Chief Scientific Officer. In this role, he manages the scientific and research aspects of the organization, ensuring that projects align with the company's goals and regulatory guidelines. He brings extensive experience in clinical research, specializing in the development and implementation of clinical studies.
Education and Expertise of Tony Giordano
Holding a PhD, Tony Giordano is well-versed in clinical research methodologies. His expertise encompasses the treatment and prevention of Peripheral Artery Disease (PAD) and conducting double-blind clinical trials. He has significant experience in research and clinical development, particularly in pharmaceuticals aimed at non-addictive pain management solutions.
Tony Giordano's Work on JAN101 Clinical Studies
Tony Giordano played a pivotal role in leading early Phase 1 and Phase 2a clinical studies for JAN101, a prospective treatment. Collaborating closely with Amol Soin, MD, JanOne’s Chief Medical Officer, he ensured the rigorous design and execution of these trials. His efforts were crucial in advancing the clinical development of JAN101.
Research and Development Contributions by Tony Giordano
Tony Giordano has led research focused on the potential development of a non-addictive pain medication. His work includes investigating the properties of sodium nitrite for promoting new blood vessel growth, expediting wound healing, and preventing tissue necrosis. Additionally, he has contributed to the development of a sustained release formulation of JAN101, aimed at enhancing its efficacy and patient compliance.